Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J M Ribera

Showing results (291-300 of 310) with videos related to

Pageof 31
Sort By:
Leukemia|October 7, 2006
Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosisN C Gutiérrez, M V Castellanos, M L Martín, et al.
Revista Espanola De Quimioterapia : Publicacion Oficial De La Sociedad Espanola De Quimioterapia|September 8, 2020
The situation of infection in the elderly in Spain: a multidisciplinary opinion documentE Bouza, F J Brenes, J Díez Domingo, et al.
Leukemia Research|June 15, 2010
Immunophenotype of acute myeloid leukemia with NPM mutations: prognostic impact of the leukemic compartment sizeJ Nomdedeu, E Bussaglia, N Villamor, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 30, 2015
Changes in the influence of lymphoma- and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphomaS K Barta, M S Samuel, X Xue, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1996
Feasibility and results of bone marrow transplantation after remission induction and intensification chemotherapy in de novo acute myeloid leukemia. Catalan Group for Bone Marrow TransplantationJ Sierra, S Brunet, A Grañena, et al.
Leukemia Research|August 13, 2005
Adverse prognostic impact of CD36 and CD2 expression in adult de novo acute myeloid leukemia patientsG Perea, A Domingo, N Villamor, et al.
Leukemia|June 7, 2017
Long-term outcome of older patients with newly diagnosed de novo acute promyelocytic leukemia treated with ATRA plus anthracycline-based therapyD Martínez-Cuadrón, P Montesinos, E Vellenga, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 5, 2024
Human immunodeficiency virus-associated lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upK Hübel, M Bower, I Aurer, et al.
Bone Marrow Transplantation|January 9, 2021
Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides and Sézary syndrome. An updated experience of the Lymphoma Working Party of the European Society for Blood and Marrow TransplantationE Domingo-Domenech, R F Duarte, A Boumedil, et al.
Haematologica|August 28, 2001
Additional cytogenetic changes do not influence the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with an ATRA plus anthracyclin based protocol. A report of the Spanish group PETHEMAJ M Hernández, G Martín, N C Gutiérrez, et al.
Pageof 31

Showing results (291-300 of 310) with videos related to

Sort By:
Pageof 31
Leukemia|October 7, 2006
Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosisN C Gutiérrez, M V Castellanos, M L Martín, et al.
Revista Espanola De Quimioterapia : Publicacion Oficial De La Sociedad Espanola De Quimioterapia|September 8, 2020
The situation of infection in the elderly in Spain: a multidisciplinary opinion documentE Bouza, F J Brenes, J Díez Domingo, et al.
Leukemia Research|June 15, 2010
Immunophenotype of acute myeloid leukemia with NPM mutations: prognostic impact of the leukemic compartment sizeJ Nomdedeu, E Bussaglia, N Villamor, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 30, 2015
Changes in the influence of lymphoma- and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphomaS K Barta, M S Samuel, X Xue, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1996
Feasibility and results of bone marrow transplantation after remission induction and intensification chemotherapy in de novo acute myeloid leukemia. Catalan Group for Bone Marrow TransplantationJ Sierra, S Brunet, A Grañena, et al.
Leukemia Research|August 13, 2005
Adverse prognostic impact of CD36 and CD2 expression in adult de novo acute myeloid leukemia patientsG Perea, A Domingo, N Villamor, et al.
Leukemia|June 7, 2017
Long-term outcome of older patients with newly diagnosed de novo acute promyelocytic leukemia treated with ATRA plus anthracycline-based therapyD Martínez-Cuadrón, P Montesinos, E Vellenga, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 5, 2024
Human immunodeficiency virus-associated lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upK Hübel, M Bower, I Aurer, et al.
Bone Marrow Transplantation|January 9, 2021
Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides and Sézary syndrome. An updated experience of the Lymphoma Working Party of the European Society for Blood and Marrow TransplantationE Domingo-Domenech, R F Duarte, A Boumedil, et al.
Haematologica|August 28, 2001
Additional cytogenetic changes do not influence the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with an ATRA plus anthracyclin based protocol. A report of the Spanish group PETHEMAJ M Hernández, G Martín, N C Gutiérrez, et al.
Pageof 31